FIG 2.

Total viable counts for the growth control and treatments with meropenem (MER) and/or tobramycin (TOB) at clinically relevant ELF concentration-time profiles sampled from the medium within the reactor, i.e., planktonic bacteria receiving meropenem monotherapy (A), tobramycin monotherapy (C), or the combination of meropenem and tobramycin (E), and from coupons, i.e., biofilm bacteria receiving meropenem monotherapy (B), tobramycin monotherapy (D), or the combination of meropenem and tobramycin (F). The results are presented as the average ± SE. The y axis starts from the limit of counting.